These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Miller AE; Wolinsky JS; Kappos L; Comi G; Freedman MS; Olsson TP; Bauer D; Benamor M; Truffinet P; O'Connor PW; Lancet Neurol; 2014 Oct; 13(10):977-86. PubMed ID: 25192851 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Chitnis T; Banwell B; Kappos L; Arnold DL; Gücüyener K; Deiva K; Skripchenko N; Cui LY; Saubadu S; Hu W; Benamor M; Le-Halpere A; Truffinet P; Tardieu M; Lancet Neurol; 2021 Dec; 20(12):1001-1011. PubMed ID: 34800398 [TBL] [Abstract][Full Text] [Related]
8. Low-density lipoprotein apheresis: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2007; 7(5):1-101. PubMed ID: 23074505 [TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of Plasma Exchange and Immunoadsorption in Neuroinflammatory Diseases. Dorst J; Fillies F; Dreyhaupt J; Senel M; Tumani H J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32899499 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B; Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apheresis therapy in AQP4 antibody-positive NMOSD attack: A propensity score-matched cohort study. Xu Y; Wang H; Song T; Yin L; Yao Y; Wei Y; Cong H; Sun J; Zhang X; Tian DC CNS Neurosci Ther; 2024 May; 30(5):e14780. PubMed ID: 38790106 [TBL] [Abstract][Full Text] [Related]
12. Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis. Lipphardt M; Wallbach M; Koziolek MJ J Clin Med; 2020 May; 9(5):. PubMed ID: 32466101 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of dual-lead thalamic deep brain stimulation for patients with treatment-refractory multiple sclerosis tremor: a single-centre, randomised, single-blind, pilot trial. Oliveria SF; Rodriguez RL; Bowers D; Kantor D; Hilliard JD; Monari EH; Scott BM; Okun MS; Foote KD Lancet Neurol; 2017 Sep; 16(9):691-700. PubMed ID: 28642125 [TBL] [Abstract][Full Text] [Related]
14. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L; Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074 [TBL] [Abstract][Full Text] [Related]
15. A prospective study comparing tryptophan immunoadsorption with therapeutic plasma exchange for the treatment of chronic inflammatory demyelinating polyneuropathy. Lieker I; Slowinski T; Harms L; Hahn K; Klehmet J J Clin Apher; 2017 Dec; 32(6):486-493. PubMed ID: 28485075 [TBL] [Abstract][Full Text] [Related]
16. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475 [TBL] [Abstract][Full Text] [Related]
17. Immunoadsorption or plasma exchange in the treatment of autoimmune encephalitis: a pilot study. Heine J; Ly LT; Lieker I; Slowinski T; Finke C; Prüss H; Harms L J Neurol; 2016 Dec; 263(12):2395-2402. PubMed ID: 27604620 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. Cree BAC; Cutter G; Wolinsky JS; Freedman MS; Comi G; Giovannoni G; Hartung HP; Arnold D; Kuhle J; Block V; Munschauer FE; Sedel F; Lublin FD; Lancet Neurol; 2020 Dec; 19(12):988-997. PubMed ID: 33222767 [TBL] [Abstract][Full Text] [Related]
19. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. Koziolek MJ; Tampe D; Bähr M; Dihazi H; Jung K; Fitzner D; Klingel R; Müller GA; Kitze B J Neuroinflammation; 2012 Apr; 9():80. PubMed ID: 22537481 [TBL] [Abstract][Full Text] [Related]